Answers are grounded in this paper and cite their sources.
Concizumab is a once-daily prophylactic treatment developed for patients with hemophilia A or B (HA/HB) with or without inhibitors. It is the first treatment for hemophilia patients to be delivered subcutaneously using a pre-filled, multi-dose pen-injector with a 4 mm, 32 G needle.
No takes yet. Share an insight, caveat, or question.
Rasmussen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: